These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

147 related items for PubMed ID: 10908001

  • 1. A multisite study of the effectiveness of methamphetamine treatment: an initiative of the Center for Substance Abuse Treatment.
    Herrell JM, Taylor JA, Gallagher C, Dawud-Noursi S.
    J Psychoactive Drugs; 2000; 32(2):143-7. PubMed ID: 10908001
    [Abstract] [Full Text] [Related]

  • 2. The CSAT methamphetamine treatment program: research design accommodations for "real world" application.
    Huber A, Lord RH, Gulati V, Marinelli-Casey P, Rawson R, Ling W.
    J Psychoactive Drugs; 2000; 32(2):149-56. PubMed ID: 10908002
    [Abstract] [Full Text] [Related]

  • 3. Methamphetamine abuse: issues for special populations.
    Freese TE, Obert J, Dickow A, Cohen J, Lord RH.
    J Psychoactive Drugs; 2000; 32(2):177-82. PubMed ID: 10908005
    [Abstract] [Full Text] [Related]

  • 4. Treatment-as-usual in the methamphetamine treatment project.
    Galloway GP, Marinelli-Casey P, Stalcup J, Lord R, Christian D, Cohen J, Reiber C, Vandersloot D.
    J Psychoactive Drugs; 2000; 32(2):165-75. PubMed ID: 10908004
    [Abstract] [Full Text] [Related]

  • 5. The CSAT methamphetamine treatment project: what are we trying to accomplish?
    Anglin MD, Rawson RA.
    J Psychoactive Drugs; 2000; 32(2):209-10. PubMed ID: 10908009
    [No Abstract] [Full Text] [Related]

  • 6. Moving research into community settings in the CSAT methamphetamine treatment project: the coordinating center perspective.
    Rawson RA, McCann MJ, Huber A, Marinelli-Casey P, Williams L.
    J Psychoactive Drugs; 2000; 32(2):201-8. PubMed ID: 10908008
    [Abstract] [Full Text] [Related]

  • 7. A descriptive analysis of participant characteristics and patterns of substance use in the CSAT methamphetamine treatment project: the first six months.
    Reiber C, Galloway G, Cohen J, Hsu JC, Lord RH.
    J Psychoactive Drugs; 2000; 32(2):183-91. PubMed ID: 10908006
    [Abstract] [Full Text] [Related]

  • 8. When treatment meets research: clinical perspectives from the CSAT Methamphetamine Treatment Project.
    Obert JL, Brown AH, Zweben J, Christian D, Delmhorst J, Minsky S, Morrisey P, Vandersloot D, Weiner A.
    J Subst Abuse Treat; 2005 Apr; 28(3):231-7. PubMed ID: 15857723
    [Abstract] [Full Text] [Related]

  • 9. Conducting trials in community settings: the provider perspective.
    Zweben JE, Cohen JB, Obert J, Vandersloot D, Marinelli-Casey P.
    J Psychoactive Drugs; 2000 Apr; 32(2):193-9. PubMed ID: 10908007
    [Abstract] [Full Text] [Related]

  • 10. The matrix model of outpatient stimulant abuse treatment: history and description.
    Obert JL, McCann MJ, Marinelli-Casey P, Weiner A, Minsky S, Brethen P, Rawson R.
    J Psychoactive Drugs; 2000 Apr; 32(2):157-64. PubMed ID: 10908003
    [Abstract] [Full Text] [Related]

  • 11. A multi-site comparison of psychosocial approaches for the treatment of methamphetamine dependence.
    Rawson RA, Marinelli-Casey P, Anglin MD, Dickow A, Frazier Y, Gallagher C, Galloway GP, Herrell J, Huber A, McCann MJ, Obert J, Pennell S, Reiber C, Vandersloot D, Zweben J, Methamphetamine Treatment Project Corporate Authors.
    Addiction; 2004 Jun; 99(6):708-17. PubMed ID: 15139869
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Grant award to the Division of Mental Health and Developmental Disabilities, Department of Health and Social Services, State of Alaska. Center for Substance Abuse Treatment (CSAT), Center for Mental Health Services (CMHS), Substance Abuse and Mental Health Services Administration (SAMHSA), HHS. Availability of grant funds for the Division of Mental Health and Developmental Disabilities, Department of Health and Social Services, State of Alaska.
    Fed Regist; 1999 Apr 16; 64(73):18922-3. PubMed ID: 10558551
    [Abstract] [Full Text] [Related]

  • 14. A profile of the substance abuse treatment industry: organization, costs, and treatment completion.
    Woodward AM, Raskin IE, Blacklow B.
    Subst Use Misuse; 2008 Apr 16; 43(5):647-79. PubMed ID: 18393082
    [Abstract] [Full Text] [Related]

  • 15. Co-occurring disorders in the adolescent mental health and substance abuse treatment systems.
    Turner WC, Muck RD, Muck RJ, Stephens RL, Sukumar B.
    J Psychoactive Drugs; 2004 Dec 16; 36(4):455-62. PubMed ID: 15751483
    [Abstract] [Full Text] [Related]

  • 16. History of the methamphetamine problem.
    Anglin MD, Burke C, Perrochet B, Stamper E, Dawud-Noursi S.
    J Psychoactive Drugs; 2000 Dec 16; 32(2):137-41. PubMed ID: 10908000
    [Abstract] [Full Text] [Related]

  • 17. Organizational and client determinants of cost in outpatient substance abuse treatment.
    Beaston-Blaakman A, Shepard D, Horgan C, Ritter G.
    J Ment Health Policy Econ; 2007 Mar 16; 10(1):3-13. PubMed ID: 17417043
    [Abstract] [Full Text] [Related]

  • 18. Substance abuse treatment with rural adolescents: issues and outcomes.
    Hall JA, Smith DC, Easton SD, An H, Williams JK, Godley SH, Jang M.
    J Psychoactive Drugs; 2008 Mar 16; 40(1):109-20. PubMed ID: 18472670
    [Abstract] [Full Text] [Related]

  • 19. Drug treatment takes a hit. As substance abuse has surged among teens, coverage for care has been curtailed.
    Gardner J.
    Mod Healthc; 1996 Oct 21; 26(43):66, 68, 70-2. PubMed ID: 10172795
    [No Abstract] [Full Text] [Related]

  • 20. Methamphetamine: an epidemic of oral health neglect, loss of access to care, abuse, and violence.
    Assael LA.
    J Oral Maxillofac Surg; 2005 Sep 21; 63(9):1253-4. PubMed ID: 16122586
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.